Analysis of prognostic value of TP53 gene mutations in non-small cell lung cancer;Analiza rokowniczego znaczenia mutacji genu TP53 u chorych na niedrobnokomórkowego raka płuca

Pneumonologia i Alergologia Polska

Volumn 73, Issue 3, 2005, Pages 264-269

  Szymanowska, Amelia ^a   Jassem, Ewa ^b   Dziadziuszko, Rafał ^c   Skrzypski, Marcin ^a   Kobierska Gulida, Grazyna ^c   Holm, Karolina ^d   Borg, Ake ^d   Rzyman, Witold ^e   Limon, Janusz ^c   Jassem, Jacek ^b  

^a Klinika Alergologii   (Poland)

^b Klinika Onkologii I Radioterapii   (Poland)

^c Zakład Patomorfologii ^*  (Poland)

^d LUND UNIVERSITY   (Sweden)

^e Klinika Chirurgii Klatki Piersiowej   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PROGNOSIS; PROTEIN ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SMOKING; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 33645971611     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Amatschek S i wsp. Tissue-Wide Expression Profiling Using cDNA Subtraction and Microarrays to Identify Tumor-Specific Genes Cancer Res 2004, 64, 844-856.
2. Chiba I i wsp. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 1990; 5: 1603-1610.
3. de Anta JM i wsp. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 1997; 15: 2951-2958.
4. Fujita T i wsp. Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int J Oncol 1999; 15: 927-934.
5. Fukuyama Y i wsp. K-ras and P53 mutations are an independent unfavourable prognostic indicator in patients with non-small cell lung cancer. Br J Cancer 1997; 75: 1125-1130.
6. Hashimoto T i wsp. P53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 1999; 59: 5572-5577.
7. Horio Y i wsp. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993; 53: 1-9.
8. Huang C i wsp. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 1998; 16: 2469-2477.
9. Isobe T i wsp. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn J Cancer Res 1994; 85: 1240-1246.
10. Jassem E i wsp. Types and localisation of P53 gene mutations: a report on 332 non-small cell lung cancer patients. Lung Cancer 2001; 34 (2 Suppl): S47-S51.
11. Jassem J i wsp. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Cancer 2004; 100: 1951-1960.
12. Kondo K i wsp. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 1996; 61: 20-26.
13. Marchetti A i wsp. P53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993; 85: 2846-2851.
14. Meert AP i wsp. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 2003; 89: 959-965.
15. Mitsudomi T i wsp. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000; 6: 4055-4063.
16. Mitsudomi T i wsp. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 2018-2023.
17. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
18. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-1276.
19. Niklińska W i wsp. P53 gene mutation and protein expression in operable non-small cell lung cancer in Poland. Eur J Cancer Prev 2000; 9: 81-87.
20. Nikliński J i wsp. Prognostic molecular markers in non-small cell lung cancer. Lung Cancer 2001; 34: S53-S58.
21. Rusin M i wsp. Molecular epidemiological study of non-small cell lung cancer from an environmentally polluted region of Poland. Br J Cancer 1999; 80: 1445-1452.
22. Ryberg D i wsp. P53 mutations in lung cancer tumors: relationship to putative susceptibility markers for cancer. Cancer Res 1994; 54: 1551-1555.
23. Tagawa M, Murata M, Kimura H. Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. Cancer Letters 1998; 128: 93-99.
24. Takagi i wsp. Distinct mutational spectrum of the P53 gene in lung cancers from Chinese women in Hong-Kong. Cancer Res 1995; 55: 5354-5357.
25. Tomizawa Y i wsp. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 1999; 18: 1007-1014.
26. Tonon G i wsp. High-resolution genomic profiles of human lung cancer. PNAS 2005; 27: 9625-9630.
27. Wang X i wsp. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol Biomarkers Prev 1995; 4: 543-548.
28. Wang YC i wsp. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Cancer Res 1998; 58: 328-333.